TuHURA enters exclusivity agreement with Kineta for KVA12123

TuHURA Biosciences and Kintara Therapeutics (KTRA) announced TuHURA has entered into an exclusivity and right of first offer agreement with Kineta (KA) for the potential acquisition of Kineta’s KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset. Under the terms of the agreement, TuHURA will pay Kineta $5M, with $2.5M paid at signing and, subject to certain provisions, an additional $2.5M to be paid by July 15. In conjunction with the agreement, TuHURA sold $5M of shares of its common stock in a private offering to an existing shareholder. The exclusivity period under the agreement lasts for 90 days, subject to extension for an additional 20 days.